Sol-Gel Technologies develops and commercializes topical dermatological medications, primarily using its proprietary silica-based delivery technologies. It markets the FDA-approved products TWYNEO for the treatment of acne vulgaris and EPSOLAY for papulopustular rosacea, while advancing clinical candidates such as SGT-610 for Gorlin syndrome and other rare skin disorders. The company operates from Israel and partners with global pharmaceutical firms to reach patients in multiple countries.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 1 | — | -8.8 | — |
| Q2 2025 | 17.3 | — | 11.6 | — |
| Q3 2025 | 0.4 | — | -5.9 | — |
| Q4 2025 | 0.7 | — | -3 | — |
| Q1 2026 | 0.1 | -89.5% | -3.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: FreightCar America, Inc. (RAIL), SIGA Technologies, Inc. (SIGA), Hudson Technologies, Inc. (HDSN), CF Bankshares Inc. (CFBK), OP Bancorp (OPBK), Eagle Financial Services, Inc. (EFSI)